An acute crossover infusion study (n=8) found exenatide-glucagon co-infusion raised myocardial glucose uptake and a diastolic strain rate marker in type 2 diabetes. PICO summary and expert commentary.
Browsing: Cardiovascular Outcomes
An open-label randomized trial in newly diagnosed type 2 diabetes found acarbose and vildagliptin both lowered plasma TMAO, with a greater fall on acarbose. PICO summary and expert commentary.
A 223-patient randomised trial found single-pill rosuvastatin 10 mg plus ezetimibe was non-inferior, not superior, to rosuvastatin 20 mg for LDL-C lowering in ASCVD and type 2 diabetes. PICO summary and expert commentary.
Design paper for the DAPA ACT HF-TIMI 68 trial testing in-hospital dapagliflozin versus placebo in 2,401 patients with acute heart failure; no efficacy results are reported. PICO summary and expert commentary.
A biomarker substudy of the EMPEROR program shows empagliflozin activates the erythropoietin-erythroferrone-hepcidin axis and raises haemoglobin in heart failure. PICO summary and expert commentary.
A pooled analysis of three finerenone trials found a modest reduction in new-onset atrial fibrillation/flutter across the cardio-kidney-metabolic spectrum. PICO summary and expert commentary.
A small secondary analysis of the EDICT randomised trial reports that initial triple therapy was associated with slower carotid intima-media thickness progression and lower liver fat than sequential add-on therapy at matched glycaemic control. PICO summary and expert commentary.
A small randomized trial compared perindopril plus indapamide against perindopril plus moxonidine (both with metformin) for left ventricular and renal protection in hypertension with prediabetes. PICO summary and expert commentary.
A secondary analysis of the CORDIOPREV trial reports that a lower baseline neutrophil count is associated with type 2 diabetes remission in patients with coronary heart disease following a Mediterranean diet. PICO summary and expert commentary.
A post-hoc pooled analysis of four randomised trials found once-weekly semaglutide lowered the composite of cardiovascular death or worsening heart failure events in patients with HFpEF, with no significant effect on cardiovascular death alone. PICO summary and expert commentary.